Bailard, Inc. Protara Therapeutics, Inc. Transaction History
Bailard, Inc.
- $3.84 Billion
- Q4 2024
A detailed history of Bailard, Inc. transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Bailard, Inc. holds 29,769 shares of TARA stock, worth $122,945. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,769Holding current value
$122,945% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TARA
# of Institutions
41Shares Held
11.6MCall Options Held
9KPut Options Held
1.8K-
Ra Capital Management, L.P. Boston, MA1.9MShares$7.85 Million0.05% of portfolio
-
Opaleye Management Inc. Boston, MA1.68MShares$6.94 Million0.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.36MShares$5.61 Million0.0% of portfolio
-
Stem Point Capital LP New York, NY943KShares$3.89 Million0.52% of portfolio
-
Woodline Partners LP San Francisco, CA852KShares$3.52 Million0.01% of portfolio
About Protara Therapeutics, Inc.
- Ticker TARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,267,400
- Market Cap $46.5M
- Description
- Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...